There are 2789 resources available
OneRemission: An integrative oncologist in your pocket
Presenter: Misha Tyulenev
Session: How can technology & data support the cancer patient journey?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
177Lu-dotatate
Presenter: Eric Baudin
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Hepatic arterial embolization
Presenter: Jonathan Strosberg
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Q&A
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Eleni Efstathiou
Session: Presidential Symposium 2 – Discussion session I: Genitourinary tumours, prostate
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Florian Lordick
Session: Presidential Symposium 2 – Discussion session II: Gastrointestinal tumours
Resources:
Slides
Webcast
LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Presenter: Edward Garon
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast